摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

harringtonine | 62624-24-2

中文名称
——
中文别名
——
英文名称
harringtonine
英文别名
(Ξ)-2-hydroxy-2-(3-hydroxy-3-methyl-butyl)-succinic acid 1-((3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl) ester 4-methyl ester;Harringtonin/Epiharringtonin;epi-Harringtonine;Harringtonine;(2'Ξ)-harringtonine;1-O-[(2S,3S,6R)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),4,13,15(19)-tetraen-3-yl] 4-O-methyl 2-hydroxy-2-(3-hydroxy-3-methylbutyl)butanedioate
harringtonine化学式
CAS
62624-24-2
化学式
C28H37NO9
mdl
——
分子量
531.603
InChiKey
HAVJATCHLFRDHY-GRYSOXMCSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    679.4±55.0 °C(Predicted)
  • 密度:
    1.35±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.5
  • 重原子数:
    38
  • 可旋转键数:
    10
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.64
  • 拓扑面积:
    124
  • 氢给体数:
    2
  • 氢受体数:
    10

SDS

SDS:7261cb8fdbfb62b775dd327568f258aa
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    (Ξ)-2-benzyloxy-2-(3-hydroxy-3-methyl-butyl)-succinic acid 1-((3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl) ester 4-methyl ester 在 palladium on activated charcoal 氢气 作用下, 以 溶剂黄146 为溶剂, 生成 harringtonine
    参考文献:
    名称:
    Preparation of harringtonine from cephalotaxine
    摘要:
    DOI:
    10.1021/jo01315a015
点击查看最新优质反应信息

文献信息

  • HARRINGTONINES SALTS, IN PARTICULAR RETINOATES, THEIR PROCESS OF PREPARATION AND THEIR USES IN THE TREATMENT OF LEUKEMIAS, CANCERS, AUTOIMMUNE, SKIN, ALZHEIMER'S AND INFLAMMATORY BOWEL DISEASES AND VIRAL INFECTIONS, COMBINED WITH MYELOPOIESIS STIMULATING AGENTS
    申请人:Robin, Jean-Pierre
    公开号:EP3763715A1
    公开(公告)日:2021-01-13
    The present invention relates to salt of the following formula (I): Another object of the invention is a method for preventing or treating diseases selected among cancer, leukemias, lymphomas, myelodysplastic syndrome, autoimmune diseases, skin diseases, neurological diseases such as Alzheimer's disease, inflammatory bowel disease, such as Crohn's disease, and viral infections including papillomavirus comprising administering to a patient in need thereof an effective dose of the salt of formula (I) or a pharmaceutical composition comprising thereof. The present invention also relates to a method of preparation of the salt of formula (I).
    本发明涉及以下式(I)的盐: 另一个本发明的目的是提供一种用于预防或治疗所选疾病的方法,所选疾病包括癌症、白血病、淋巴瘤、骨髓增生异常综合症、自身免疫性疾病、皮肤病、神经系统疾病如阿尔茨海默病、炎症性肠病如克罗恩病,以及包括乳头状瘤病毒在内的病毒感染,其包括向需要该盐的患者施用公式(I)的盐或包含其的药物组合物的有效剂量。 本发明还涉及制备公式(I)的盐的方法。
  • Preparation of harringtonine from cephalotaxine
    作者:T. Ross Kelly、Robert W. McNutt、Michel Montury、Nicholas P. Tosches、K. L. Mikolajczak、C. R. Smith、D. Weisleder
    DOI:10.1021/jo01315a015
    日期:1979.1
查看更多

同类化合物

高三尖杉酯碱酰胺 高三尖杉酯碱 氧桥三尖杉碱 异三尖杉酯碱 双(去甲基)-脱氧三尖杉酯碱 去甲基三尖杉酮碱 去氧哈林通碱 乙酰三尖杉碱 三尖杉酯碱 三尖杉碱 4-羟基三尖杉碱 4'-去甲基高三尖杉酯碱 (1S,3aR)-1,5,6,8,9,14bbeta-六氢-2-甲氧基-4H-环戊并[a][1,3]二氧杂环戊并[4,5-H]吡咯并[2,1-b][3]苯并氮杂卓-1alpha,9alpha-二醇 (-)-脱水三尖杉酯碱 nordeoxyharringtonine cephalotaxine 4′-demethylharringtonine homoharringtonine α-N-oxide cephalotaxine α-N-oxide cephalotaxine α-N-oxide cephalotaxine β-N-oxide (2R,3R,4S,5S)-2,3-bis(tert-butyldiphenylsilyloxy)-cephalotaxan-8-one (2S,3R,5S,7S)-3-methyl-4,17,19-trioxa-11-azahexacyclo[12.7.0.02,7.03,5.07,11.016,20]henicosa-1(21),14,16(20)-triene (2S,6S)-3-methyl-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),3,13,15(19)-tetraene (1S)-2-methoxy-(3atC4,14bt)-1,5,6,8,9,14b-hexahydro-4H-1r,9c-epioxido-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepine 1-O-[(2R,3S,6R)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),4,13,15(19)-tetraen-3-yl] 4-O-methyl 2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate 2,3,5,6,8,9-hexahydro-1-(pivaloyloxy)-4H-cyclopenta<1,3>dioxolo<4,5-h>pyrrolo<2,1-b><3>benzazepine Dimethyl 3-(trifluoromethylsulfonyloxy)-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),2,7,13,15(19)-pentaene-7,8-dicarboxylate Alkaloid D Epicephalotaxin Cephalotaxin a u. b (3aα,4aS*,15bβ,15cα)-(+/-)-3a,4,6,7,9,10,15b,15c-octahydro-2,2-dimethyl-5H-<1,3>dioxolo<4,5-h>-1,3-dioxolo<4,5>cyclopenta<1,2-a>pyrrolo<2,1-b><3>-benzazepine 4-Hydroxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),13,15(19)-trien-3-one (Ξ)-2-methyl-2-(2,2,2-trichloro-ethoxycarbonyloxy)-butyric acid (3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl ester (3aR)-2-methoxy-1t-(2,2,2-trichloro-ethoxycarbonyloxy)-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepine (S)-phenyl-(2,2,2-trichloro-ethoxycarbonyloxy)-acetic acid (3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl ester oxalic acid ethyl ester (3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl ester (3aR)-1t-benzyloxycarbonyloxy-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepine (S)-hydroxy-phenyl-acetic acid (3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl ester [(2S,3S,6R)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),4,13,15(19)-tetraen-3-yl] (2R)-2-[2-(furan-2-ylmethylamino)-2-oxoethyl]-2,6-dihydroxy-6-methylheptanoate (+/-)-3-dehydroxy-2-demethoxy-1,2-dihydro-2,8-dioxocephalotaxine epi-deoxyharringtonine hexa-2t,4t-dienoic acid (3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl ester Dehydrodeoxyhomoharringtonine [(2S,4S,6S)-12-methylsulfanyl-11-oxo-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),13,15(19)-trien-4-yl] acetate Omacetaxine mepesuccinate hydrochloride cephalotaxinamide (1R,2S,3aS,14bR)-1,2,3,5,6,8,9,14b-Octahydro-4H-cyclopenta<1,3>dioxolo<4,5-h>pyrrolo<2,1-b><3>benzazepine-1,2-diol methylfumaric acid 1-((3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl) ester 4-methyl ester 11alpha-Hydroxycephalotaxine